Author:
Berri Richard N.,Ford Jennifer M.
Publisher
Springer International Publishing
Reference77 articles.
1. Zhu Y, Hanna N, Boutros C, Alexander HR Jr. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol. 2013;4(1):62–71.
2. Esquivel J. Surgical oncology clinics of North America: treatment of peritoneal malignancies. Surg Oncol Clin North Am. 2012;21:4.
3. Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224–30.
4. Elias D, Goéré D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et al. Results of a systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247(3):445–50.
5. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20–6.